Turner's syndrome patients lack tight junctions between uterine epithelial cells

Rogers, Peter A. W.; Murphy, Christopher R.; Leeton, John; Hosie, Margot J.; Beaton, L.

doi:10.1093/oxfordjournals.humrep.a137754

Cited by 26 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is some evidence that Turner syndrome patients have an altered uterine environment [14,15]. However we found no evidence in the literature of a potential link between mothers with Turner syndrome and offspring with Goldenhar syndrome.…”

Section: Discussioncontrasting

confidence: 79%

See 1 more Smart Citation

Case report: Goldenhar syndrome following donor oocyte IVF

Gittins

Kasraie

2010

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 79%

“…The evidence that the uterine environment might differ in women with Turner syndrome [14,15] and the 'recipient's hypothyroidism [16] are worthy of discussion but suggestion of a causal link would be extremely speculative.…”

Section: Resultsmentioning

confidence: 99%

Case report: Goldenhar syndrome following donor oocyte IVF

Gittins

Kasraie

2010

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…A structurally abnormal uterus, autoimmune mechanisms and/or diminished endometrial receptivity due to longterm hypoestrogenism may also increase spontaneous abortion rates in women with TS (229).…”

Section: Assisted Reproductive Technologies With Oocyte Donation (Od)mentioning

confidence: 99%

Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting

Gravholt¹,

Andersen

Conway

et al. 2017

European Journal of Endocrinology

908

1,259

View full text Add to dashboard Cite

Turner syndrome affects 25-50 per 100,000 females and can involve multiple organs through all stages of life, necessitating multidisciplinary approach to care. Previous guidelines have highlighted this, but numerous important advances have been noted recently. These advances cover all specialty fields involved in the care of girls and women with TS. This paper is based on an international effort that started with exploratory meetings in 2014 in both Europe and the USA, and culminated with a Consensus Meeting held in Cincinnati, Ohio, USA in July 2016. Prior to this meeting, five groups each addressed important areas in TS care: 1) diagnostic and genetic issues, 2) growth and development during childhood and adolescence, 3) congenital and acquired cardiovascular disease, 4) transition and adult care, and 5) other comorbidities and neurocognitive issues. These groups produced proposals for the present guidelines. Additionally, four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with a separate systematic review of the literature. These four questions related to the efficacy and most optimal treatment of short stature, infertility, hypertension, and hormonal replacement therapy. The guidelines project was initiated by the European Society of Endocrinology and the Pediatric Endocrine Society, in collaboration with the European Society for Paediatric Endocrinology, the Endocrine Society, the European Society of Human Reproduction and Embryology, the American Heart Association, the Society for Endocrinology, and the European Society of Cardiology. The guideline has been formally endorsed by the European Society of Endocrinology, the Pediatric Endocrine Society, the European Society for Paediatric Endocrinology, the European Society of Human Reproduction and Embryology and Summary of recommendationsThe recommendations (R) are worded as recommend (strong recommendation) and suggest (weak recommendation). We formally graded only the evidence underlying recommendations for therapeutic choices. The quality of evidence behind the recommendations is classified as very low (⨁◯◯◯), low (⨁⨁◯◯), moderate (⨁⨁⨁◯) and strong (⨁⨁⨁⨁). See further section 'Summary of methods used for guideline development'. Diagnosis and geneticsR 1.1. We recommend considering a diagnosis of TS in phenotypic females with a karyotype containing one X chromosome and complete or partial absence of the second sex chromosome, associated with one or more typical clinical manifestations of TS (⨁⨁⨁⨁). R 1.2. We recommend against considering a diagnosis of TS in females with one X chromosome and a deletion distal to Xq24 on the other X chromosome, and in women over the age of 50 years with less than 5% 45,X mosaicism (⨁⨁◯◯). R 1.3. We suggest that the new general surveillance management guideline applies to TS patients with any karyotype (⨁⨁◯◯). R 1.4. We recommend to consider testing for Turner syndrome (TS) in a female with typical signs (Table 2) (⨁⨁⨁⨁). R 1.5. We ...

show abstract

“…At the beginning, the pregnancy results were not as good as they were among other women with ovarian failure [15,16], and some inherent problems in the endometrium were suspected. But larger surveys later on have resulted in similar pregnancy rates as are obtained among other women with ovarian failure [17][18][19][20][21].…”

Section: Oocyte Donation In Turner Syndromementioning

confidence: 90%